Acura Pharmaceuticals Inc. has amended its secured promissory note agreement with Abuse Deterrent Pharma, LLC. The updated loan schedule, dated October 23, 2025, reflects a series of additional loans made to Acura Pharmaceuticals since the original note was issued on November 10, 2022. The amendment documents a progression of individual loans, with principal amounts ranging from $100,000 to $125,000, extending through October 23, 2025. As a result of these additional loans, the aggregated principal under the agreement has increased to $8,994,279. The amendment was signed by Robert A. Seiser, Senior Vice President and CFO of Acura Pharmaceuticals.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acura Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-101984), on October 24, 2025, and is solely responsible for the information contained therein.